REFERENCES
- Campanacci Memiligh grade osteosarcomas. In: Bone and soft tissue tumors , 2 ed. Wien, New York: Springer-Verlag, 1999: 463–515
- Ferrari S, Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol. 2007; 19 (6): 341–6
- Hurria A, Lichtman SM. Pharmacokinetics of chemother-apy in the older patient. Cancer Control. 2007; 14 (1): 32–43
- Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther. 2007; 82 (1): 87–96
- Stephenson T. How children's responses to drugs differ from adults. Br J Clin Pharmacol. 2005; 59 (6): 670–3
- Verrill MW, Judson IR, Wiltshaw E, Thomas JM, Harmer CL, Fisher C. The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing's family tumours. Ann Oncol. 1997; 8 (11): 1099–105
- Singh S, Parulekar W, Murray N, Feld R, Evans WK, Tu D et al. Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol. 2005; 23 (4): 850–6
- Klimm B, Reineke T, Haverkamp H, Behringer K, Eich HT, Josting A et al. German Hodgkin Study Group. Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. J Clin Oncol. 2005; 23 (31): 8003–11
- Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P et al. Italian and Scandinavian Sarcoma Groups. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with local-ized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 2005; 23 (34): 8845–52
- Pollock BH, Birch JM. Registration and classification of adolescent and young adult cancer cases. Pediatr Blood Cancer 2008; 50 (5 suppl): 1090–1093
- Eselgrim M, Grunert H, Kuhne T, Zoubek A, Kevric M, Burger H et al. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials. Pediatr Blood Cancer. 2006; 47 (1): 42–50
- Lewis U, Weeden S, Machin D, Stark D, Craft AW. Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup. J Clin Oncol. 2000; 18 (24): 4028–37
- Juergens C, Weston C, Lewis I, Whelan J, Paulussen M, Oberlin 0 et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial Pediatr Blood Cancer. 2006; 47 (1): 22–9
- Scripture CD, Sparreboom A, Figg WD. Modulation of cytochrome P450 activity: Implications for cancer therapy. Lancet Oncol 2005, 6 (10): 780–789
- Fujita K. Cytochrome P450 and anticancer drugs. Curr Drug Metab 2006, 7 (1): 23–37
- Bebia Z, Such SC, Wilson JW, Frye RF, Romkes M, Cec-chetti A et al: Bioequivalence revisited: Influence of age and sex on CYP enzymes. Clin Pharmacol Ther 2004, 76 (6): 618–627
- Hempel G, Flege S, Wörthwein G, Boos J. Peak plasma concentrations of doxorubicin in children with acute lym-phoblastic leukemia or non-Hodgkin lymphoma. Cancer Chemother Pharmacol 2002, 49 (2): 133–41
- Eksborg S, Palm C, Bjork O. A comparative pharmacoki-netic study of doxorubicin and 4'-epi-doxorubicin in children with acute lymphocytic leukemia usign a limited sampling procedure. Anticancer Drugs 2000, 11 (2): 129–136
- Frost BM, Eksborg S, Björk O, Abrahamsson J, Behrendtz M, Castor A et al: Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: Multi-institutional collaborative study. Med Pediatr Oncol 2002, 38 (5): 329–337
- Chen CS, Lin JT, Goss KA, He YA, Halpert JR, Wax-man DJ. et al. Activation of the anticancer prodrugs cyclophos-phamide and ifosfamide: Identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinet-ics. Mol Pharmacol 2004, 65 (5): 1278–1285
- Furlanut M, Franceschi L. Pharmacology of ifos-famide.Oncology. 2003; 65 Suppl 2: 2–6.
- Soddy AV, Yule SM, Wyllie R, Price L, Pearson AD, Idle JR. Intrasubject variation in children of ifosfamide pharmacoki-netics and metabolism during repeated administration. Cancer Chemother Pharmacol. 1996; 38 (2): 147–54
- Dobbs NA, Twelves CJ, Gillies H, James CA, Harper PG, Rubens RD.Gender affects doxorubicin pharmacokinetics in Patients with normal liver biochemistry. Cancer Chemother Phar-macol 1995, 36 (6): 473–476